Modulators of miR-323-3p for the Prevention or Treatment of Rheumatoid Arthritis
AssigneeUniversitat Zurich Prorektorat MNW
InventorsSteffen Gay, Mary Connolly, Caroline Ospelt
Life of this patent
Estimating the term…
Abstract
A miR-323-3p inhibitor is provided for the prevention or therapy of rheumatoid arthritis, comprising a sequence capable of forming a hybrid to miR-323-3p as an oligonucleotide or a vector from which such oligonucleotide is transcribed, or as a miRNA decoy or sponge.
Claims14
-12. (canceled)
A method for treating rheumatoid arthritis in a patient in need thereof, comprising administering to the patient a miR-323-3p inhibitor, wherein the miR-323-3p inhibitor comprises a hybridizing sequence of nucleotides, wherein said hybridizing sequence is capable of forming a hybrid to SEQ ID 1 or SEQ ID 2;
- thereby treating the rheumatoid arthritis.
A method for treating rheumatoid arthritis in a patient in need thereof,
- comprising administering to the patient a virus particle comprising:
- a transcribed sequence comprising a decoy sequence tract at least 90% identical to sequence of SEQ ID 1 or SEQ ID 2 or
- a sequence being capable of forming a hybrid to SEQ ID 1 or SEQ ID 2, wherein the sequence is under control of a polymerase promoter sequence operable in a mammalian cell;
- thereby treating the rheumatoid arthritis.
Dependencies are inferred from the claim text.